Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study

NCT00390689 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00390689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
Not reported
Enrollment
154 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic restless legs syndrome